Drug Approval | October 13, 2021
Dr Reddy’s launch anti-cancer drug in China
Abiraterone by Dr Reddy's becomes the first anti-cancer drug from India to enter the Chinese market
Abiraterone by Dr Reddy's becomes the first anti-cancer drug from India to enter the Chinese market
BDMP is a personalised program delivered through the Breathe app to assist people with Type 2 Diabetics to achieve healthy outcomes
Since its inception, the company has either acquired or taken a majority stake in five companies
An amount of Rs. 70.9 crore has been earmarked for funding capital expenditure for the proposed expansion
_256_384.jpg)
The two doses of Covaxin are likely to be administered to children with a gap of 28 days
Conventional Itraconazole mainstay drug to fight fungal infection has high result variance and low patient compliance because of dosing dependence upon food, acidic beverage and antacid consumption
This opens up a huge market for the company’s Magnezis implants in India
Now all districts of the country will have commissioned PSA Oxygen plants
The company has already received the emergency use authorization (EUA) from the Drug Controller General of India (DCGI) for ZyCoV-D to be administered in three doses on August 20
The company claims to be a market leader in core orthopaedic and gynaecology segments like bone and joint disorders, pain management and, pregnancy and women’s nutrition
Subscribe To Our Newsletter & Stay Updated
